<Summary id="CDR0000799719" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>This evidence-based, expert-reviewed summary discusses the clinical features, molecular features and treatment of pediatric gastrointestinal stromal tumors (GIST).</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-gist-treatment-pdq">Childhood Gastrointestinal Stromal Tumors (PDQ®): Treatment</SummaryURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038161">gastrointestinal stromal tumor</TermRef></MainTopics><SummaryAbstract><Para id="_1556">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pediatric gastrointestinal stromal tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_1557">This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>pediatric gastrointestinal stromal tumors</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Gastrointestinal Stromal Tumors Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Gastrointestinal Stromal Tumors Treatment</AltTitle><SummarySection id="_848"><Title>Incidence</Title><Para id="_849">Gastrointestinal stromal tumors  (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract in adults.<Reference refidx="1"/> These tumors are rare in children.<Reference refidx="2"/> Approximately 2%  of all GIST  occur in children and young adults.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> In one series, pediatric GIST accounted for 2.5% of all pediatric nonrhabdomyosarcomatous soft tissue sarcomas.<Reference refidx="6"/> Previously, these tumors were  diagnosed as leiomyomas, leiomyosarcomas, and leiomyoblastomas.</Para><Para id="_1292">In pediatric patients, GIST are most commonly located in the stomach and almost exclusively affect adolescent females.<Reference refidx="5"/><Reference refidx="7"/><Reference refidx="8"/></Para><ReferenceSection><Citation idx="1" PMID="15365079">Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (18): 3813-25, 2004.</Citation><Citation idx="2" PMID="22069178">Pappo AS, Janeway K, Laquaglia M, et al.: Special considerations in pediatric gastrointestinal tumors. J Surg Oncol 104 (8): 928-32, 2011.</Citation><Citation idx="3" PMID="15838387">Prakash S, Sarran L, Socci N, et al.: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27 (4): 179-87, 2005.</Citation><Citation idx="4" PMID="16160481">Miettinen M, Lasota J, Sobin LH: Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29 (10): 1373-81, 2005.</Citation><Citation idx="5" PMID="19499582">Benesch M, Wardelmann E, Ferrari A, et al.: Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer 53 (7): 1171-9, 2009.</Citation><Citation idx="6" PMID="15221987">Cypriano MS, Jenkins JJ, Pappo AS, et al.: Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 101 (1): 39-50, 2004.</Citation><Citation idx="7" PMID="19248968">Pappo AS, Janeway KA: Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23 (1): 15-34, vii, 2009.</Citation><Citation idx="8" PMID="21486690">Benesch M, Leuschner I, Wardelmann E, et al.: Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). Eur J Cancer 47 (11): 1692-8, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_1330"><Title>Clinical Features</Title><Para id="_1331">Most pediatric patients with gastrointestinal stromal tumors  (GIST) are diagnosed during the second decade of life with anemia-related gastrointestinal bleeding. In addition, pediatric GIST have a high propensity for multifocality (23%) and nodal metastases.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> These features may account for the high incidence of local recurrence seen in this patient population. Despite these features, patients have an indolent course, characterized by multiple tumor recurrences and long survival rates.<Reference refidx="2"/></Para><ReferenceSection><Citation idx="1" PMID="19248968">Pappo AS, Janeway KA: Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23 (1): 15-34, vii, 2009.</Citation><Citation idx="2" PMID="18483389">Agaram NP, Laquaglia MP, Ustun B, et al.: Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 (10): 3204-15, 2008.</Citation><Citation idx="3" PMID="19499582">Benesch M, Wardelmann E, Ferrari A, et al.: Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer 53 (7): 1171-9, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_1327"><Title>Histology and Molecular Features</Title><Para id="_1328">Histologically, pediatric gastrointestinal stromal tumors  (GIST) have a predominance of epithelioid or epithelioid/spindle cell morphology. Unlike adult GIST, the mitotic rate does not appear to accurately predict clinical behavior in pediatric patients.<Reference refidx="1"/><Reference refidx="2"/> Most GIST in the pediatric age range have loss of the succinate dehydrogenase (SDH) complex and consequently, lack SDHB expression by immunohistochemistry.<Reference refidx="3"/><Reference refidx="4"/> In addition, these tumors have minimal large-scale chromosomal changes and overexpress the insulin-like growth factor 1 receptor.<Reference refidx="5"/><Reference refidx="6"/> </Para><Para id="_2394">Gastrointestinal tumors without a definitive line of differentiation should be evaluated for <GeneName>NTRK</GeneName> alterations.<Reference refidx="7"/> Mesenchymal tumor of the gastrointestinal tract is characterized by the presence of <GeneName>NTRK</GeneName> rearrangements and  is a separate entity from GIST. In a report of eight cases of mesenchymal tumors, six occurred in children. Four of these patients had lesions that were enriched for <GeneName>NTRK3</GeneName> fusions, consistent with the diagnosis of infantile fibrosarcoma of the gastrointestinal tract.<Reference refidx="7"/></Para><Para id="_2425">Activating variants of <GeneName>KIT</GeneName> and <GeneName>PDGFRA</GeneName>, which are seen in 90% of adult GIST,  are present in only a small fraction of pediatric GIST.<Reference refidx="1"/><Reference refidx="5"/><Reference refidx="8"/> </Para><Para id="_1329">The lack of SDHB expression in most pediatric GIST implicates cellular respiration defects in the pathogenesis of this disease and supports the notion that this disease is better categorized as SDH-deficient GIST.  Furthermore, about 50% of patients with SDH-deficient GIST have germline pathogenic variants of the <GeneName>SDH</GeneName> complex, most commonly involving <GeneName>SDHA</GeneName>.<Reference refidx="3"/> This finding supports the concept that SDH-deficient GIST is a cancer predisposition syndrome, and  testing of affected patients for constitutional variants for the <GeneName>SDH</GeneName> complex should be considered.<Reference refidx="9"/></Para><Para id="_851">SDH-deficient GIST can arise within the context of the following two syndromes:<Reference refidx="1"/><Reference refidx="10"/></Para><ItemizedList id="_852" Style="bullet"><ListItem><Strong>Carney triad.</Strong> Carney  triad is a syndrome characterized by the occurrence of GIST, lung chondromas, and paragangliomas. In addition, about 20% of patients have adrenal adenomas and 10% have esophageal leiomyomas. GIST are the most common (75%) presenting lesions in these patients. To date, no coding sequence variants of <GeneName>KIT</GeneName>, <GeneName>PDGFRA</GeneName>, or the <GeneName>SDH</GeneName> genes have been found in these patients.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></ListItem><ListItem><Strong>Carney-Stratakis syndrome.</Strong> Carney-Stratakis syndrome is characterized by paraganglioma and GIST  caused by germline pathogenic variants of the <GeneName>SDHB</GeneName>, <GeneName>SDHC</GeneName>, and <GeneName>SDHD</GeneName> genes.<Reference refidx="4"/><Reference refidx="13"/></ListItem></ItemizedList><Para id="_2426"> A small percentage of SDH-deficient GIST lack somatic or germline variants of the <GeneName>SDH</GeneName> complex. These tumors are characterized by SDHC promoter hypermethylation and gene silencing, and they are categorized as GIST with an <GeneName>SDHC</GeneName> epigenetic variant.<Reference refidx="14"/></Para><Para id="_2072">In an observational study done at the National Cancer Institute, 116 patients with presumed wild-type GIST were evaluated, and 95 of these patients had an adequate tumor specimen available for molecular profiling.  Among these 95 patients, the investigators identified the following three distinctive subgroups of patients:<Reference refidx="15"/></Para><ItemizedList id="_2073" Style="bullet"><ListItem>  <Strong>Group 1 (SDH-competent GIST):</Strong> Group 1 included 11 patients who were designated as SDH competent because of positive staining of SDHB and lack of variants on sequencing.  All of these patients were adults, the median age was 46 years, and 64% were female.  The tumors arose primarily in the small bowel (9 of 11). One patient had metastases to the peritoneum, and one patient had multifocal disease. Variant analysis of these tumors identified variants in the <GeneName>BRAF</GeneName>, <GeneName>NF1</GeneName>, <GeneName>CBL</GeneName>, <GeneName>KIT</GeneName>, and <GeneName>ARID1A</GeneName> genes. With a median follow-up of 8 years, three of these patients (27%) died of progressive disease.</ListItem><ListItem><Strong>Group 2 (<GeneName>SDHX</GeneName>-variant GIST):</Strong> Group 2 included 63 patients who were SDH deficient. Variants were observed in the <GeneName>SDHA</GeneName> (n = 34), <GeneName>SDHB</GeneName> (n = 16), <GeneName>SDHC</GeneName> (n = 12), and <GeneName>SDHD</GeneName> (n = 1) complexes. Of the 38 patients with <GeneName>SDH</GeneName>-variant GIST who had matching germline and tumor DNA, 31 (82%) had the same variant detected in the germline and the tumor.  This group of patients was younger (median age, 23 years), mostly female (62%), and presented with gastric tumors (100%) and multifocal disease (42%). Metastases at presentation were seen in the lymph nodes (65%), liver (21%), and peritoneum (10%). At a median follow-up from diagnosis of 6 years, three patients (5%) had died.</ListItem><ListItem><Strong>Group 3 (GIST with an <GeneName>SDHC</GeneName> epigenetic variant):</Strong> Group 3  included 21 patients with SDH-deficient tumors, with <GeneName>SDHC</GeneName> promoter methylation and  no structural variants.  The median age at diagnosis was younger (age 15 years), and  most patients were female (95%). All tumors arose in the stomach; 72% were multifocal. Metastases were present at diagnosis in the liver (37%), peritoneum (5%), and lymph nodes (38%). At a median follow-up of 7 years, one patient (5%) with GIST with an <GeneName>SDHC</GeneName> epigenetic variant died of their disease.</ListItem></ItemizedList><Para id="_2074">Of the 95 patients that were evaluated at this clinic, 18 patients had syndromic GIST (i.e., Carney triad or Carney-Stratakis syndrome).  Among the Carney triad patients, two patients had the complete triad, five patients had <GeneName>SDH</GeneName> variants, and six patients had epigenetic variants. Seven patients with Carney-Stratakis syndrome had <GeneName>SDH</GeneName>-variant GIST (n = 6) or GIST with an <GeneName>SDHC</GeneName> epigenetic variant (n = 1).<Reference refidx="15"/></Para><ReferenceSection><Citation idx="1" PMID="19248968">Pappo AS, Janeway KA: Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23 (1): 15-34, vii, 2009.</Citation><Citation idx="2" PMID="17090188">Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130 (10): 1466-78, 2006.</Citation><Citation idx="3" PMID="24886695">Miettinen M, Lasota J: Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol 53: 514-9, 2014.</Citation><Citation idx="4" PMID="21997692">Miettinen M, Wang ZF, Sarlomo-Rikala M, et al.: Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 35 (11): 1712-21, 2011.</Citation><Citation idx="5" PMID="17909012">Janeway KA, Liegl B, Harlow A, et al.: Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67 (19): 9084-8, 2007.</Citation><Citation idx="6">Tarn C, Rink L, Merkel E, et al.: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences  105 (24): 8387-92, 2008. <ExternalRef xref="http://www.pnas.org/content/105/24/8387.full.pdf">Also available online</ExternalRef>. Last accessed June 04, 2019.</Citation><Citation idx="7" PMID="32669612">Atiq MA, Davis JL, Hornick JL, et al.: Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol 34 (1): 95-103, 2021.</Citation><Citation idx="8" PMID="18483389">Agaram NP, Laquaglia MP, Ustun B, et al.: Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 (10): 3204-15, 2008.</Citation><Citation idx="9" PMID="21173220">Janeway KA, Kim SY, Lodish M, et al.: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 108 (1): 314-8, 2011.</Citation><Citation idx="10" PMID="21663639">Otto C, Agaimy A, Braun A, et al.: Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad. Diagn Pathol 6: 52, 2011.</Citation><Citation idx="11" PMID="19723753">Carney JA: Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab 94 (10): 3656-62, 2009.</Citation><Citation idx="12" PMID="19499582">Benesch M, Wardelmann E, Ferrari A, et al.: Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer 53 (7): 1171-9, 2009.</Citation><Citation idx="13" PMID="17667967">Pasini B, McWhinney SR, Bei T, et al.: Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16 (1): 79-88, 2008.</Citation><Citation idx="14" PMID="25540324">Killian JK, Miettinen M, Walker RL, et al.: Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 6 (268): 268ra177, 2014.</Citation><Citation idx="15" PMID="27011036">Boikos SA, Pappo AS, Killian JK, et al.: Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2 (7): 922-8, 2016.</Citation></ReferenceSection></SummarySection><SummarySection id="_1864"><SectMetaData><SectionType>Unusual Cancers Special Considerations</SectionType></SectMetaData><Title>Special Considerations for the Treatment of Children With Cancer</Title>

<Para id="_1864_md_3">Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.<Reference refidx="1"/>    Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills
of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation
to achieve optimal survival and quality of life:</Para>
        <ItemizedList id="_1864_md_4" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Pathologists.</ListItem><ListItem>Pediatric radiation
oncologists.</ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Ophthalmologists.</ListItem><ListItem> Rehabilitation
specialists.</ListItem><ListItem>Pediatric oncology nurses.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child-life professionals.</ListItem><ListItem>Psychologists.</ListItem><ListItem>Nutritionists.</ListItem></ItemizedList>
 <Para id="_1864_md_5">For specific information about supportive care for children and adolescents with cancer, see the summaries on <ExternalRef xref="https://www.cancer.gov/publications/pdq/information-summaries/supportive-care">Supportive and Palliative Care</ExternalRef>.</Para><Para id="_1864_md_6">The American Academy of Pediatrics has outlined guidelines for
pediatric cancer centers and their role in the treatment of children and adolescents
with cancer.<Reference refidx="2"/>  At
these centers, clinical trials are available for most  types of cancer that occur in children and adolescents, and the opportunity
to participate is offered to most patients and their families.  Clinical
trials for children and adolescents diagnosed with cancer are generally
designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis.  Most of the progress in identifying curative
therapies for childhood cancers has been achieved through clinical trials. 
Information about ongoing clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_1864_md_7">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment.  For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>.</Para>
<Para id="_1864_md_8">Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.<Reference refidx="6"/> The U.S. <ExternalRef xref="https://www.congress.gov/107/plaws/publ280/PLAW-107publ280.pdf">Rare Diseases Act of 2002</ExternalRef> defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.</Para><Para id="_1864_md_9">The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.<Reference refidx="7"/><Reference refidx="8"/> In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:</Para><ItemizedList id="_1864_md_10" Style="bullet"><ListItem>A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included  in the very rare group due to a lack of knowledge and expertise in the management of these tumors.<Reference refidx="9"/></ListItem><ListItem>The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).<Reference refidx="10"/>  These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.<Reference refidx="4"/><Para id="_11"> Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.</Para></ListItem></ItemizedList><Para id="_1864_md_12">These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.</Para><Para id="_1837">Information about these tumors may also be found in sources relevant to
adults with cancer, such as <SummaryRef href="CDR0000639481" url="/types/soft-tissue-sarcoma/hp/gist-treatment-pdq">Gastrointestinal Stromal Tumors Treatment</SummaryRef>.</Para><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2">American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics  134 (2): 410-4, 2014. <ExternalRef xref="https://pediatrics.aappublications.org/content/134/2/410">Also available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4">National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://NCCRExplorer.ccdi.cancer.gov/">Available online</ExternalRef>. Last accessed February 25, 2025.</Citation><Citation idx="5">Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. 	Bethesda, MD: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statistics-network/explorer/">Available online</ExternalRef>. Last accessed December 30, 2024.</Citation><Citation idx="6" PMID="24488779">Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr.</Citation><Citation idx="7" PMID="28687376">Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017.</Citation><Citation idx="8" PMID="28542893">DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017.</Citation><Citation idx="9" PMID="30785015">Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019.</Citation><Citation idx="10" PMID="20956621">Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_858"><Title>Treatment of Childhood Gastrointestinal Stromal Tumors</Title><Para id="_2427">Treatment options for pediatric gastrointestinal stromal tumors (GIST) include the following:</Para><OrderedList id="_2428" Style="Arabic"><ListItem>Observation.</ListItem><ListItem>Surgery.</ListItem><ListItem>Targeted therapy.</ListItem></OrderedList><Para id="_859">Once the diagnosis of pediatric GIST is established, patients should be referred to medical centers with expertise in the treatment of GIST.<Reference refidx="1"/><Reference refidx="2"/>  </Para><Para id="_1860">Given the indolent course of the disease in pediatric patients, it is reasonable to avoid extensive initial surgeries and to withhold subsequent resections unless needed to address symptoms such as obstruction or bleeding.<Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_860">Tumor samples are evaluated for variants in <GeneName>KIT</GeneName> (exons 9, 11, 13, 17), <GeneName>PDGFRA</GeneName> (exons 12, 14, 18), and <GeneName>BRAF</GeneName> (V600E).<Reference refidx="1"/><Reference refidx="2"/> Treatment options for GIST depend on whether a variant is detected.</Para><Para id="_2429"><Strong>GIST with a <GeneName>KIT</GeneName> or <GeneName>PDGFRA</GeneName> variant:</Strong> Pediatric patients  who harbor <GeneName>KIT</GeneName> or <GeneName>PDGFRA</GeneName> variants are managed like adults. For more information, see <SummaryRef href="CDR0000639481" url="/types/soft-tissue-sarcoma/hp/gist-treatment-pdq">Gastrointestinal Stromal Tumors Treatment</SummaryRef>.</Para><Para id="_2430"><Strong>Succinate dehydrogenase (SDH)-deficient GIST:</Strong> Approximately one-half of all patients with wild-type GIST are SDH deficient.<Reference refidx="5"/> For most pediatric patients with SDH-deficient GIST, surgical resection of localized disease is recommended because of its indolent course. Extensive surgery and repeated surgical resections should be avoided. </Para><Para id="_2431">This approach is supported by a study of 76 patients with wild-type GIST who underwent surgery for newly diagnosed and recurrent disease.<Reference refidx="5"/></Para><ItemizedList id="_2432" Style="bullet"><ListItem>Only 9% of patients experienced a fatal event, whereas 71% (54 patients) developed tumor recurrence or progression at a median of 2.5 years. </ListItem><ListItem>For this population, the 1-year event-free survival (EFS) rate was 73%, the 5-year EFS rate was 24%, and the 10-year EFS rate was 16%. </ListItem><ListItem>Factors associated with an increased risk of recurrence included metastatic disease and elevated mitotic rate. SDH status and extent of surgical resection did not influence the risk of recurrence. </ListItem><ListItem>Among 33 patients who underwent reoperation for recurrent disease, each subsequent resection was associated with a lower EFS rate.</ListItem></ItemizedList><Para id="_2433">In patients with SDH-deficient GIST, responses to imatinib, regorafenib, vandetanib, sunitinib, and guadecitabine   are uncommon.<Reference refidx="3"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/></Para><OrderedList id="_2436" Style="Arabic"><ListItem> In a review of ten patients who were treated with imatinib mesylate, one patient experienced a partial response and three patients had stable disease.<Reference refidx="3"/> </ListItem><ListItem>In the phase III SWOG Cancer Research Network intergroup <ProtocolRef nct_id="NCT00009906">S0033 (NCT00009906)</ProtocolRef> trial, 20 tumors from patients presumed to have wild-type  disease were resequenced.<Reference refidx="8"/> <ItemizedList id="_2437" Style="bullet"><ListItem>Twelve of these tumors were identified as having <GeneName>SDH</GeneName>  variants, and only one patient (8.3%) experienced a partial response to imatinib.<Reference refidx="10"/></ListItem></ItemizedList></ListItem><ListItem> In another study, sunitinib appeared to show more activity.<Reference refidx="11"/><ItemizedList id="_2438" Style="bullet"><ListItem>In six children with imatinib-resistant GIST, one patient had a partial response, and five patients had stable disease.</ListItem></ItemizedList> </ListItem><ListItem>The combination of olaparib and temozolomide produced symptomatic relief and response in one pediatric patient with multiply relapsed SDH-deficient GIST who had osseous and mediastinal disease.<Reference refidx="12"/></ListItem><ListItem>In a phase II trial of guadecitabine, no partial or complete responses were seen in seven patients (aged 18–57 years) with recurrent or refractory SDH-deficient GIST.<Reference refidx="13"/></ListItem></OrderedList><Para id="_2435">Unlike recommendations for adults, the use of adjuvant imatinib cannot be recommended in children with SDH-deficient GIST.<Reference refidx="14"/></Para><ReferenceSection><Citation idx="1" PMID="17624289">Demetri GD, Benjamin RS, Blanke CD, et al.: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 (Suppl 2): S1-29; quiz S30, 2007.</Citation><Citation idx="2" PMID="22248968">Janeway KA, Weldon CB: Pediatric gastrointestinal stromal tumor. Semin Pediatr Surg 21 (1): 31-43, 2012.</Citation><Citation idx="3" PMID="19248968">Pappo AS, Janeway KA: Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23 (1): 15-34, vii, 2009.</Citation><Citation idx="4" PMID="22069178">Pappo AS, Janeway K, Laquaglia M, et al.: Special considerations in pediatric gastrointestinal tumors. J Surg Oncol 104 (8): 928-32, 2011.</Citation><Citation idx="5" PMID="28029307">Weldon CB, Madenci AL, Boikos SA, et al.: Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol 35 (5): 523-528, 2017.</Citation><Citation idx="6" PMID="31773431">Neppala P, Banerjee S, Fanta PT, et al.: Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev 38 (3): 525-535, 2019.</Citation><Citation idx="7" PMID="17046465">Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (9544): 1329-38, 2006.</Citation><Citation idx="8" PMID="12181401" MedlineID="22169285">Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (7): 472-80, 2002.</Citation><Citation idx="9" PMID="37559050">Martin-Broto J, Valverde C, Hindi N, et al.: REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer 22 (1): 127, 2023.</Citation><Citation idx="10" PMID="28196207">Heinrich MC, Rankin C, Blanke CD, et al.: Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3 (7): 944-952, 2017.</Citation><Citation idx="11" PMID="19326424">Janeway KA, Albritton KH, Van Den Abbeele AD, et al.: Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 52 (7): 767-71, 2009.</Citation><Citation idx="12" PMID="36151992">Singh C, Bindra RS, Glazer PM, et al.: Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide. Pediatr Blood Cancer 70 (3): e30020, 2023.</Citation><Citation idx="13" PMID="36302175">Ligon JA, Sundby RT, Wedekind MF, et al.: A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. Clin Cancer Res 29 (2): 341-348, 2023.</Citation><Citation idx="14" PMID="19303137">Dematteo RP, Ballman KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373 (9669): 1097-104, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_1960"><Title>Treatment Options Under Clinical Evaluation for Childhood Gastrointestinal Stromal Tumors</Title><Para id="_1961">Information about National Cancer Institute (NCI)–supported clinical trials can be found on the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">NCI website</ExternalRef>. For information about clinical trials sponsored by other organizations, see the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov website</ExternalRef>.</Para></SummarySection><SummarySection id="_2305"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (09/05/2024)</Title><Para id="_2306">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_2440">This summary was comprehensively reviewed.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000799719#_AboutThis_1" url="/types/soft-tissue-sarcoma/hp/child-gist-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pediatric gastrointestinal stromal tumors. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Gastrointestinal Stromal Tumors Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Denise Adams, MD (Children's Hospital Boston)</ListItem><ListItem>Karen J. Marcus, MD, FACR (Dana-Farber of Boston Children's Cancer Center and Blood Disorders Harvard Medical School)</ListItem><ListItem>William H. Meyer, MD</ListItem><ListItem>Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)</ListItem><ListItem>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>Alberto S. Pappo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>D. Williams Parsons, MD, PhD (Texas Children's Hospital)</ListItem><ListItem>Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)</ListItem><ListItem>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</ListItem><ListItem>Stephen J. Shochat, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Gastrointestinal Stromal Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-gist-treatment-pdq">https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-gist-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 31661204]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2019-10-22</DateFirstPublished><DateLastModified>2024-09-05</DateLastModified></Summary>
